
CLAIMS

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of compound 1:




1,

or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in the manufacture of a medicament for the treatment of a fungal infection in a human subject;

wherein,

the fungal infection in the subject is caused by *Candida* spp., *Aspergillus* spp., *Scedosporium* spp., *Fusarium* spp., *Paecilomyces* spp., *Purpureocillium* spp., *Dematiaceous* spp., *Rhizopus*, *Mucor* spp., *Lichtheimia* spp., *Cunninghamella* spp., *Acremonium* spp., *Rasamsonia* spp., *Scedosporium* spp., *Schizophyllum* spp., *Trichoderma* spp., *Alternaria* spp., *Cladophialophora* spp., *Cladosporium* spp., *Exophiala* spp., *Fonsecaea* spp., *Lomentospora* spp., *Phialophora* spp., *Scopulariopsis* spp., *Magnusiomyces* (*Geotrichum)* spp., *Trichosporon* spp., *Malassezia* spp., *Saprochaete* spp., *Kodamaea* spp., *Rhodotorula* spp., *Saccharomyces* spp., *Pseudozyma* spp., *Sporobolomyces* spp., *Exophiala* spp., *Lacazia* spp., *Emmonsia* spp., *Wickerhamomyces (Pichia)* spp., *Emergomyces* spp., *Talaromyces* spp., or a combination thereof;

the therapeutically effective amount of compound 1 provides a steady state 24-hr Area Under the Concentration-Time Curve ($AUC_{0\text{-}24}$) in the subject of at least about 150 µg×hr/mL of compound 1A:



1A;

wherein the subject has a contradiction to standard of care antifungal therapy due to chronic kidney disease (CKD); and

wherein the treatment comprises daily administration of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for at least 1-4 weeks;

wherein the treatment regimen comprises a loading dose of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and a maintenance dose of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof;

wherein the loading dose of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, is 2000 mg; and

wherein the maintenance dose comprises once daily administration of 600 mg to 1500 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2. The use of claim 1, wherein chronic kidney disease (CKD) is Stage 3 CKD, Stage 4 CKD, or Stage 5 CKD.

3. The use of claim 1, wherein chronic kidney disease (CKD) is Stage 3 CKD or, Stage 4 CKD.

4. The use of any one of claims 1-3, wherein the pharmaceutical composition is not contraindicated in subjects with chronic kidney disease.

5. The use of claims 1-4, wherein the subject has high levels of protein in his or her urine (proteinuria).

6. The use of any one of claims 1-5, wherein the loading dose of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprises the administration of two doses of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject by intravenous (I.V.) infusion;

wherein the loading dose comprises administration of 1000 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject by intravenous (I.V.) infusion followed by a second administration of 1000 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject by intravenous (I.V.) infusion within 24 hours of the first infusion.

7. The use of claim 6, wherein each loading dose of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered to the subject over 30 minutes to 4 hours.

8. The use of any one of claims 1-7, wherein the maintenance dose is administered once daily starting on the second day of treatment.

9. The use of any one of claims 1-8, wherein the maintenance dose is 600 mg to 1200 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and is administered over a period of 30 minutes to 4 hours by I.V. infusion starting on the second, third, or fourth day of treatment.

10. The use of any one of claims 1-9, wherein the maintenance dose is 800 mg to 1000 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and is administered orally once daily to the subject starting on the second, third, or fourth day of treatment.

11. The use of any one of claims 1-10, wherein, starting on the second, third, or fourth day of treatment:

a) 600 mg to 900 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of 30 minutes to 3 hours by I.V. infusion; or

b) 700 mg to 1000mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered orally once daily.

12. The use of any one of claims 1-11, wherein, starting on the second day of treatment:

a) 600 mg to 900 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of 30 minutes to 3 hours by I.V. infusion; or

b) 700 mg to 1000mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered orally once daily.

13. The use of any one of claims 1-11, wherein, starting on the second day of treatment, about 600 mg to about 900 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of 30 minutes to 3 hours by I.V. infusion; and starting on the fourth day of treatment:

a) 600 mg to 900 mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of 30 minutes to 3 hours by I.V. infusion; or

b) 700 mg to 1000mg of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered orally once daily.